Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma

Published:2015-11-26 Issue:2 Volume:91 Page:179-184
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Maurer Matthew J.¹,Jais Jean-Philippe²,Ghesquières Hervé³⁴,Witzig Thomas E.⁵,Hong Fangxin⁶,Haioun Corinne⁷,Thompson Carrie A.⁵,Thieblemont Catherine⁸,Micallef Ivana N.⁵,Porrata Luis F.⁵,Ribrag Vincent⁹,Nowakowski Gregorz S.⁵,Casasnovas Olivier¹⁰,Bologna Serge¹¹,Morschhauser Franck¹²,Morrison Vicki A.¹³¹⁴,Peterson Bruce A.¹³,Macon William R.¹⁵,Copie-Bergman Christiane¹⁶,Feldman Andrew L.¹⁵,Syrbu Sergei I.¹⁷,Kurtin Paul J.¹⁵,Gascoyne Randy D.¹⁸,Li Hailun⁶,Allmer Cristine¹,Kahl Brad S.¹⁹,Ansell Stephen M.⁵,Slager Susan L.¹,Link Brian K.¹⁷,Salles Gilles⁴²⁰,Habermann Thomas M.⁵,Tilly Hervé²¹,Cerhan James R.¹

Affiliation:

1. Department of Health Sciences Research; Mayo Clinic; Rochester Minnesota

2. Department of Biostatistics; Necker Hospital, INSERM UMRS 872, AP-HP; Paris France

3. Department of Medical Oncology; Centre Léon Bérard; Lyon France

4. Centre National De La Recherche Scientifique (CNRS), Unite Mixte De Recherche (UMR); Université Claude Bernard; Lyon France

5. Division of Hematology; Mayo Clinic; Rochester Minnesota

6. Department of Biostatistics & Computational Biology; Harvard T.H. Chan; Boston Massachusetts

7. Lymphoid Malignancies Unit, Henri Mondor Hospital; Université Paris-Est; Créteil France

8. Hematology; APHP, Hôpital Saint Louis, INSERM U728, IUH; Paris France

9. Department of Medical Oncology; Institut Gustave Roussy; Villejuif France

10. Hopital Le Bocage; Dijon France

11. Department of Hematology; Centre Hospitalier Nancy-Brabois; Vandoeuvre France

12. Department of Hematology; Centre Hospitalier Régional Universitaire De Lille; Lille France

13. Department of Medicine; University of Minnesota; Minneapolis Minnesota

14. Veterans Affairs Medical Center; Minneapolis Minnesota

15. Department of Laboratory Medicine and Pathology; Mayo Clinic; Rochester Minnesota

16. INSERM Unité U955 Équipe 9; Créteil France

17. Department of Pathology; University of Iowa College of Medicine; Iowa City Iowa

18. Centre for Lymphoid Cancers; British Columbia Cancer Agency; Vancouver British Columbia Canada

19. Department of Medicine; Washington University, St. Louis; Missouri

20. Department of Hematology; Hospices Civils De Lyon; Pierre Benite France

21. Department of Hematology; INSERM U918, IRIB, Centre Henri Becquerel; Rouen France

Funder

National Institutes of Health to the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence; The Henry J. Predolin Foundation

Publisher

Wiley

Subject

Hematology

Reference30 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J Clin Oncol,2006

3. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

4. Relapsed/refractory diffuse large B-cell lymphoma;Friedberg;Hematol Am Soc Hematol Educ Program,2011

5. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy;Maurer;J Clin Oncol,2014

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials;Leukemia & Lymphoma;2024-01-05

2. Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS;Annals of Hematology;2023-12-01

3. Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models;Blood Cancer Journal;2023-10-13

4. Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study;Annals of Hematology;2023-06-12

5. Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL;2023-06-10